Propranolol ameliorates and epinephrine exacerbates progression of acute and chronic viral myocarditis

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 289, Issue 4 58-4, 2005, Pages

  Wang, Ju Feng ^a   Meissner, Achim ^c   Malek, Sohail ^a   Chen, Yu ^a   Ke, Qingen ^a   Zhang, Jielin ^b   Chu, Victor ^a   Hampton, Thomas G ^a   Crumpacker, Clyde S ^b   Abelmann, Walter H ^a   Amende, Ivo ^a   Morgan, James P ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Cardiovascular Division   (Germany)

Author keywords

adrenergic receptor stimulation; blocker; Arrhythmia; Encephalomyocarditis virus; Heart failure; Proinflammatory cytokines

Indexed keywords

ADRENALIN; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; PROPRANOLOL;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CHRONIC DISEASE; CONTROLLED STUDY; CYTOKINE GENE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; ENCEPHALOMYOCARDITIS VIRUS; GENE; GENE EXPRESSION REGULATION; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE NECROSIS; INFLAMMATORY CELL; INTERLEUKIN 10 GENE; INTERLEUKIN 6 GENE; MALE; MORTALITY; MOUSE; MOUSE STRAIN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SUDDEN DEATH; SURVIVAL RATE; TUMOR NECROSIS FACTOR ALPHA GENE; VIRUS MYOCARDITIS;

ACUTE DISEASE; ADRENERGIC AGONISTS; ADRENERGIC BETA-ANTAGONISTS; AMNION; ANIMALS; ARRHYTHMIA; CARDIOVIRUS INFECTIONS; CHRONIC DISEASE; CYTOKINES; DEATH, SUDDEN, CARDIAC; ENCEPHALOMYOCARDITIS VIRUS; EPINEPHRINE; GENE EXPRESSION; HUMANS; MALE; MICE; MICE, INBRED BALB C; MYOCARDITIS; PROPRANOLOL;

EID: 25444508188     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00258.2005     Document Type: Article

References (38)

1. Brown CA and O'Connell JB. Myocarditis and idiopathic dilated cardiomyopathy. Am J Med 99: 309-314, 1995.
2. Caspi J, Coles JG, Benson LN, Herman SL, Diaz RJ, Augustine J, Brezina A, Kolin A, and Wilson GJ. The protective effect of magnesium on acute catecholamine cardiotoxicity in the neonate. J Thorac Cardiovasc Surg 105: 523-531, 1993.
3. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, and Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311: 819-823, 1984.
4. Cook-Mills JM, Cohen RL, Perlman RL, and Chambers DA. Inhibition of lymphocyte activation by catecholamines: evidence for a non-classical mechanism of catecholamine action. Immunology 85: 544-549, 1995.
5. Dong R, Liu P, Wee L, Butany J, and Sole MJ. Verapamil ameliorates the clinical and pathological course of murine myocarditis. J Clin Invest 90: 2022-2030, 1992.
6. Engel D, Peshock R, Armstong RC, Sivasubramanian N, and Mann DL. Cardiac myocyte apoptosis provokes adverse cardiac remodeling in transgenic mice with targeted TNF overexpression. Am J Physiol Heart Circ Physiol 287: H1303-H1311, 2004.
7. Grimm D, Holmer SR, Riegger GA, and Kromer EP. Effects of β-receptor blockade and angiotensin II type 1 receptor antagonism in isoproterenol-induced heart failure in the rat. Cardiovasc Pathol 8: 315-323, 1999.
8. 2-adrenoreceptor activation. Am J Physiol Endocrinol Metab 273: E1203-E1208, 1997.
9. Hatfield SM, Petersen BH, and DiMicco JA. β-Adrenoceptor modulation of the generation of murine cytotoxic T lymphocytes in vitro. J Pharmacol Exp Ther 239: 460-466, 1986.
10. Henegar JR, Schwartz DD, and Janicki JS. ANG II-related myocardial damage: role of cardiac sympathetic catecholamines and β-receptor regulation. Am J Physiol Heart Circ Physiol 275: H534-H541, 1998.
11. Hoekstra JW, Griffith R, Kelley R, Cody RJ, Lewis D, Scheatzle M, and Brown CG. Effect of standard-dose versus high-dose epinephrine on myocardial high-energy phosphates during ventricular fibrillation and closed-chest CPR. Ann Emerg Med 22: 1385-1391, 1993.
12. 1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 99: 649-654, 1999.
13. Kalinichenko VV, Mokyr MB, Graf LH Jr, Cohen RL, and Chambers DA. Norepinephrine-mediated inhibition of antitumor cytotoxic T lymphocyte generation involves a β-adrenergic receptor mechanism and decreased TNF-α gene expression. J Immunol 163: 2492-2499, 1999.
14. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death - learning from the past for the future. Circulation 99: 1091-1100, 1999.
15. Kishimoto C, Matsumori A, Ohmae M, Tomioka N, and Kawai C. Electrocardiographic findings in experimental myocarditis in DBA/2 mice: complete atrioventricular block in the acute stage, low voltage of the QRS complex in the subacute stage and arrhythmias. J Am Coll Cardiol 3: 1461-1468, 1984.
16. Kishimoto C, Kuribayashi K, Masuda T, Tomioka N, and Kawai C. Immunologic behavior of lymphocytes in experimental viral myocarditis: significance of T lymphocytes in the severity of myocarditis and silent myocarditis in BALB/c-nu/nu mice. Circulation 71: 1247-1254, 1985.
17. Levine TB, Francis GS, Goldsmith SR, Simon AB, and Cohn JN. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 49: 1659-1666, 1982.
18. 2+ current. World J Gastroenterol 10: 1171-1175, 2004.
19. Lohse MJ, Engelhardt S, and Eschenhagen T. What is the role of β-adrenergic signaling in heart failure? Circ Res 93: 896-906, 2003.
20. Madden KS and Felten DL. Experimental basis for neural-immune interactions. Physiol Rev 75: 77-106, 1995.
21. Malec PH, Zeman K, Markiewicz K, and Tchorzewski H. Chronic β-adrenergic antagonist treatment affects human T lymphocyte responsiveness "in vitro." Allergol Immunopathol 18: 83-85, 1990.
22. Mangge H, Pietsch B, Lindner W, Warnkross H, Leb G, and Schauenstein K. Enhancing in vivo effect of propranolol on human lymphocyte function is not due to stereospecific β-adrenergic blockade. Agents Actions 38: 281-285, 1993.
23. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91: 988-998, 2002.
24. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, and Marks AR. PKA phosphorylation dissociates FKBP 12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101: 365-376, 2000.
25. Mason JW. Myocarditis and dilated cardiomyopathy: an inflammatory link. Cardiovasc Res 60: 5-10, 2003.
26. Matsumori A, Wang H, Abelmann WH, and Crumpacker CS. Treatment of viral myocarditis with ribavirin in an animal preparation. Circulation 71: 834-839, 1985.
27. Morgan JP, Erny RE, Allen PD, Grossman W, and Gwathmey JK. Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure. Circulation 81 Suppl: III21-III31, 1990.
28. Murray DR, Prabhu SD, and Chandrasekar B. Chronic β-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 101: 2338-2341, 2000.
29. Nishio R, Matsumori A, Shioi T, Ishida H, and Sasayama S. Treatment of experimental viral myocarditis with interleukin-10. Circulation 100: 1102-1108, 1999.
30. Nishio R, Shioi T, Sasayama S, and Matsumori A. Carvedilol increases the production of interleukin-12 and interferon-γ and improves the survival of mice infected with the encephalomyocarditis virus. J Am Coll Cardiol 41: 340-345, 2003.
31. Reichenbach DD and Benditt EP. Catecholamines and cardiomyopathy: the pathogenesis and potential importance of myofibrillar degeneration. Hum Pathol 1: 125-129, 1970.
32. Reiken S, Gaburjakova M, Gaburjakova J, He KL, Prieto A, Becker E, Yi GH, Wang J, Burkhoff D, and Marks AR. β-Adrenergic receptor blockers restore cardiac calcium release channel (ryanodine receptor) structure and function in heart failure. Circulation 104: 2843-2848, 2001.
33. Rezkalla S, Kloner RA, Khatib G, Smith FE, and Khatib R. Effect of metoprolol in acute coxsackievirus B3 murine myocarditis. J Am Coll Cardiol 12: 412-414, 1988.
34. Shioi T, Matsumori A, and Sasayama S. Persistent expression of cytokine in the chronic stage of viral myocarditis in mice. Circulation 94: 2930-2937, 1996.
35. Terasaki F, Kitaura Y, Hayashi T, Nakayama Y, Deguchi H, and Kawamura K. Arrhythmias in coxsackie B3 virus myocarditis. Continuous electrocardiography in conscious mice and histopathology of the heart with special reference to the conduction system. Heart Vessels Suppl 5: 45-50, 1990.
36. Tominaga M, Matsumori A, Okada I, Yamada T, and Kawai C. β-Blocker treatment of dilated cardiomyopathy: beneficial effect of carteolol in mice. Circulation 83: 2021-2028, 1991.
37. Wallukat G, Morwinski M, Kowal K, Forster A, Boewer V, and Wollenberger A. Autoantibodies against the β-adrenergic receptor in human myocarditis and dilated cardiomyopathy: β-adrenergic agonism without desensitization. Eur Heart J 12: 178-181, 1991.
38. Wang JF, Zhang JL, Min JY, Sullivan MF, Ping P, Xiao YF, and Morgan JP. Cocaine enhances myocarditis induced by encephalomyocarditis virus in the murine model. Am J Physiol Heart Circ Physiol 282: H956-H963, 2002.